Janus Henderson Group PLC lowered its holdings in Agios Pharmaceuticals Inc (NASDAQ:AGIO) by 2.1% in the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 388,536 shares of the biopharmaceutical company’s stock after selling 8,418 shares during the period. Janus Henderson Group PLC owned approximately 0.80% of Agios Pharmaceuticals worth $25,935,000 at the end of the most recent reporting period.
Several other hedge funds have also made changes to their positions in AGIO. Aperio Group LLC acquired a new position in shares of Agios Pharmaceuticals in the second quarter valued at approximately $206,000. Public Employees Retirement Association of Colorado boosted its holdings in shares of Agios Pharmaceuticals by 5.2% in the 2nd quarter. Public Employees Retirement Association of Colorado now owns 6,504 shares of the biopharmaceutical company’s stock valued at $335,000 after buying an additional 323 shares in the last quarter. Janney Montgomery Scott LLC boosted its holdings in shares of Agios Pharmaceuticals by 9.7% in the 2nd quarter. Janney Montgomery Scott LLC now owns 4,820 shares of the biopharmaceutical company’s stock valued at $248,000 after buying an additional 425 shares in the last quarter. Great West Life Assurance Co. Can boosted its holdings in shares of Agios Pharmaceuticals by 84.6% in the 2nd quarter. Great West Life Assurance Co. Can now owns 5,543 shares of the biopharmaceutical company’s stock valued at $285,000 after buying an additional 2,541 shares in the last quarter. Finally, TD Asset Management Inc. boosted its holdings in shares of Agios Pharmaceuticals by 4.9% in the 2nd quarter. TD Asset Management Inc. now owns 30,000 shares of the biopharmaceutical company’s stock valued at $1,544,000 after buying an additional 1,400 shares in the last quarter. Hedge funds and other institutional investors own 93.79% of the company’s stock.
Several brokerages have recently issued reports on AGIO. Credit Suisse Group upped their target price on shares of Agios Pharmaceuticals from $61.00 to $66.00 and gave the company an “outperform” rating in a report on Thursday, November 2nd. Oppenheimer reiterated a “buy” rating and issued a $83.00 price target on shares of Agios Pharmaceuticals in a research report on Monday, December 11th. Canaccord Genuity set a $90.00 price target on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, December 12th. Zacks Investment Research upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $68.00 price target for the company in a research report on Tuesday. Finally, Cann reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, December 5th. One analyst has rated the stock with a sell rating, two have issued a hold rating and twelve have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $75.00.
In other news, insider Scott Biller sold 3,000 shares of the stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $65.00, for a total transaction of $195,000.00. Following the transaction, the insider now directly owns 56,059 shares in the company, valued at approximately $3,643,835. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Lewis Clayton Jr. Cantley sold 1,000 shares of the stock in a transaction dated Monday, October 16th. The stock was sold at an average price of $71.09, for a total transaction of $71,090.00. Following the transaction, the director now owns 84,394 shares in the company, valued at $5,999,569.46. The disclosure for this sale can be found here. Over the last three months, insiders sold 32,130 shares of company stock worth $2,039,260. 5.43% of the stock is owned by corporate insiders.
Shares of Agios Pharmaceuticals Inc (NASDAQ AGIO) traded up $2.57 on Friday, hitting $75.11. 671,099 shares of the stock were exchanged, compared to its average volume of 419,764. The stock has a market cap of $3,660.00, a P/E ratio of -11.98 and a beta of 1.83. Agios Pharmaceuticals Inc has a 1-year low of $39.24 and a 1-year high of $76.02.
Agios Pharmaceuticals (NASDAQ:AGIO) last issued its quarterly earnings data on Wednesday, November 1st. The biopharmaceutical company reported ($1.59) EPS for the quarter, beating the Zacks’ consensus estimate of ($1.78) by $0.19. The firm had revenue of $11.35 million for the quarter, compared to analysts’ expectations of $10.85 million. Agios Pharmaceuticals had a negative net margin of 506.39% and a negative return on equity of 69.64%. The firm’s revenue was up 26.4% on a year-over-year basis. During the same period in the prior year, the company earned ($1.63) EPS. sell-side analysts forecast that Agios Pharmaceuticals Inc will post -6.59 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Janus Henderson Group PLC Has $25.94 Million Stake in Agios Pharmaceuticals Inc (NASDAQ:AGIO)” was originally published by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this report on another website, it was stolen and republished in violation of US and international copyright laws. The legal version of this report can be viewed at https://www.thelincolnianonline.com/2018/01/13/janus-henderson-group-plc-sells-8418-shares-of-agios-pharmaceuticals-inc-agio-updated-updated.html.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.